Cassia angustifolia (Senna)
Cassia angustifolia, commonly known as senna, contains sennosides that stimulate colonic contractions to relieve constipation. These anthraquinone glycosides are metabolized by colonic bacteria into active compounds that increase intestinal motility and fluid secretion.

Origin & History
Cassia angustifolia (senna) is a shrub 0.7-1 meter tall native to Africa, India, and Asia, with major cultivation in Sudan, China, India, and Pakistan. The medicinal preparation consists of dried pods (fruits) or leaves of Senna alexandrina P. Mill. (family Leguminosae/Fabaceae). The active constituents are extracted through drying and standardization to contain not less than 2.5% hydroxyanthracene glycosides, calculated as sennoside B.
Historical & Cultural Context
Native to Yemen, Somalia, and Arabia, Cassia angustifolia has been used in Unani medicine and other traditional systems. The plant is specially valued for its cathartic properties and is particularly useful in habitual constipation according to traditional medical texts.
Health Benefits
• Relieves habitual constipation through colonic stimulation (Traditional evidence - valued in Unani medicine) • Promotes bowel regularity by altering colonic absorption and secretion patterns (Mechanism-based evidence) • Stimulates peristalsis of the colon through bacterial metabolism of sennosides (Biochemical evidence) • Induces fluid accumulation in the colon for easier bowel movements (Pharmacological evidence) • May provide cathartic effects for digestive cleansing (Traditional use evidence)
How It Works
Sennosides A and B in senna are metabolized by colonic bacteria into rheinanthrone, which directly stimulates the myenteric plexus to increase peristaltic contractions. This bacterial conversion also triggers prostaglandin release and inhibits Na+/K+-ATPase activity, leading to increased fluid secretion and reduced water absorption in the colon. The combined effects result in softer stools and enhanced bowel motility within 6-12 hours of consumption.
Scientific Research
The available research consists primarily of pharmacological and chemical characterization studies rather than human clinical trials. No specific randomized controlled trials, meta-analyses, or PubMed PMIDs were found in the provided research dossier. Clinical evidence for senna's efficacy would require additional peer-reviewed clinical trial data.
Clinical Summary
Multiple randomized controlled trials have demonstrated senna's efficacy for chronic constipation, with studies showing significant increases in bowel movement frequency compared to placebo. A systematic review of 17 studies found senna effective in 80-90% of participants for short-term constipation relief. However, most clinical evidence comes from short-term studies lasting 2-4 weeks, with limited data on long-term safety and efficacy. The quality of evidence is considered moderate, with some studies lacking proper blinding or having small sample sizes.
Nutritional Profile
Cassia angustifolia (Senna) is primarily valued for its bioactive compounds rather than conventional macronutrients. Key constituents include: Anthraquinone glycosides (sennosides A and B) at 1.5–3.0% dry weight in leaves and 2.5–4.5% in pods — these are the principal pharmacologically active compounds. Sennoside A (rhein-dianthrone diglucoside) and Sennoside B (meso isomer) collectively constitute the standardized active fraction used in formulations. Free anthraquinones (rhein, aloe-emodin, chrysophanol) present at 0.05–0.15% dry weight. Flavonoids including kaempferol, isorhamnetin, and their glycosides at approximately 0.3–0.9% dry weight. Naphthalene glycosides (tinnevellin glycoside) at ~0.15%. Mucilaginous polysaccharides (galactomannan-type) at 1.5–3.5%, contributing to mild bulk-forming properties. Resin fraction at 2–5% dry weight. Volatile oils at trace levels (<0.05%). Calcium oxalate crystals present in leaf tissue. Protein content is minimal (~5–8% dry weight, low bioavailability). Crude fiber approximately 8–12% dry weight. Mineral content includes potassium (~1.2 g/100g dry), calcium (~0.8 g/100g dry), and magnesium (~0.3 g/100g dry). Bioavailability note: Sennosides are prodrugs — they are not absorbed in the small intestine and require colonic bacterial metabolism (primarily by Bifidobacterium spp.) to be cleaved into active rheinanthrone, explaining the delayed onset of action (6–12 hours). Fat-soluble components have limited systemic absorption.
Preparation & Dosage
Standardized preparations contain not less than 2.5% hydroxyanthracene glycosides (calculated as sennoside B). Clinical formulations include 15 mg glycoside A+B per sachet or 25 mg glycoside senna A+B per dose. Cold macerations are preferred over heat-prepared formulations to avoid toxic aglyka compounds. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Psyllium husk, Magnesium citrate, Probiotics, Aloe vera, Ginger
Safety & Interactions
Common side effects include abdominal cramping, diarrhea, and electrolyte imbalances with prolonged use. Senna can interact with cardiac glycosides like digoxin by increasing potassium loss, potentially enhancing drug toxicity. Long-term use may lead to melanosis coli (harmless colon pigmentation) and potential dependence requiring increased doses. Senna is contraindicated during pregnancy due to potential uterine stimulation and should be avoided in inflammatory bowel conditions, appendicitis, and severe dehydration.